InsiderTrades.com logo
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

CMPX Insider Trading

Insider Ownership Percentage: 29.80%
Insider Buying (Last 12 Months): $2,609,547.90
Insider Selling (Last 12 Months): $62,561.23

Compass Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Compass Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Compass Therapeutics Share Price & Price History

Current Price: $3.24
Price Change: ▲ Price Increase of +0.03 (0.93%)
As of 03/21/2023 05:00 PM ET

This chart shows the closing price history over time for CMPX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

Compass Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/10/2023Thomas J SchuetzCEOBuy10,000$3.37$33,700.006,021,873View SEC Filing Icon  
2/27/2023Thomas J SchuetzCEOBuy20,000$3.98$79,600.006,011,873View SEC Filing Icon  
2/15/2023Thomas J SchuetzCEOBuy20,000$3.86$77,200.005,991,873View SEC Filing Icon  
1/31/2023Thomas J SchuetzCEOBuy20,000$4.05$81,000.005,471,873View SEC Filing Icon  
1/24/2023Thomas J SchuetzCEOBuy20,000$4.19$83,800.005,451,873View SEC Filing Icon  
11/25/2022Vered Bisker-LeibCOOSell2$4.36$8.721,060,414View SEC Filing Icon  
11/22/2022Vered Bisker-LeibCOOSell14,929$4.19$62,552.511,069,985View SEC Filing Icon  
11/8/2022Orbimed Advisors LlcDirectorBuy402,000$3.21$1,290,420.0015,219,994View SEC Filing Icon  
9/28/2022Thomas J SchuetzCEOBuy10,000$2.32$23,200.005,431,873View SEC Filing Icon  
9/26/2022Thomas J SchuetzCEOBuy15,000$2.27$34,050.005,421,873View SEC Filing Icon  
8/10/2022Thomas J SchuetzCEOBuy15,000$2.64$39,600.005,361,873View SEC Filing Icon  
8/1/2022Thomas J SchuetzCEOBuy15,000$2.58$38,700.005,346,873View SEC Filing Icon  
6/21/2022Thomas J SchuetzCEOBuy20,000$2.80$56,000.005,331,873View SEC Filing Icon  
6/16/2022Thomas J SchuetzCEOBuy20,000$2.34$46,800.005,311,873View SEC Filing Icon  
6/13/2022Thomas J SchuetzCEOBuy30,000$2.29$68,700.005,291,873View SEC Filing Icon  
6/6/2022Thomas J SchuetzCEOBuy30,000$2.83$84,900.005,261,873View SEC Filing Icon  
6/1/2022Thomas J SchuetzCEOBuy20,000$3.03$60,600.005,231,873View SEC Filing Icon  
5/26/2022Thomas J SchuetzCEOBuy20,000$3.04$60,800.005,211,873View SEC Filing Icon  
5/23/2022Thomas J SchuetzCEOBuy18,355$2.72$49,925.605,191,873View SEC Filing Icon  
5/13/2022Carl L GordonDirectorBuy30,722$2.49$76,497.7814,817,994View SEC Filing Icon  
5/11/2022Carl L GordonDirectorBuy64,700$1.79$115,813.0014,690,178View SEC Filing Icon  
5/10/2022Thomas J SchuetzCEOBuy27,836$1.80$50,104.805,153,303View SEC Filing Icon  
5/9/2022Orbimed Advisors LlcDirectorBuy90,712$1.56$141,510.7214,601,031View SEC Filing Icon  
5/6/2022Orbimed Advisors LlcDirectorBuy10,200$1.63$16,626.0014,510,319View SEC Filing Icon  
11/4/2021Carl L GordonDirectorBuy5,357,143$3.50$18,750,000.50View SEC Filing Icon  
See Full Table
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

SEC Filings (Institutional Ownership Changes) for Compass Therapeutics (NASDAQ:CMPX)

54.27% of Compass Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CMPX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Compass Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/21/2023B. Riley Wealth Advisors Inc.14,918$75K0.0%N/A0.012%Search for SEC Filing on Google Icon
2/15/2023Jane Street Group LLC62,829$0.32M0.0%+340.4%0.050%Search for SEC Filing on Google Icon
2/15/2023Silverarc Capital Management LLC268,307$1.35M0.4%+2.4%0.213%Search for SEC Filing on Google Icon
2/15/2023Millennium Management LLC81,947$0.41M0.0%+29.7%0.065%Search for SEC Filing on Google Icon
2/15/2023Morgan Stanley64,498$0.32M0.0%+627.0%0.051%Search for SEC Filing on Google Icon
2/15/2023Man Group plc25,305$0.13M0.0%N/A0.020%Search for SEC Filing on Google Icon
2/15/2023Braidwell LP1,814,266$9.13M0.3%N/A1.438%Search for SEC Filing on Google Icon
2/15/2023Boothbay Fund Management LLC17,130$86K0.0%N/A0.014%Search for SEC Filing on Google Icon
2/14/2023Alyeska Investment Group L.P.545,170$2.73M0.0%N/A0.432%Search for SEC Filing on Google Icon
2/14/2023Susquehanna International Group LLP455,681$2.29M0.0%+2,208.6%0.361%Search for SEC Filing on Google Icon
2/14/2023683 Capital Management LLC38,039$0.19M0.0%N/A0.030%Search for SEC Filing on Google Icon
2/14/2023Marshall Wace LLP28,296$0.14M0.0%-45.4%0.022%Search for SEC Filing on Google Icon
2/13/2023Charles Schwab Investment Management Inc.42,767$0.22M0.0%+34.8%0.034%Search for SEC Filing on Google Icon
2/13/2023Vivo Capital LLC3,557,630$17.90M2.1%+77.9%2.819%Search for SEC Filing on Google Icon
2/13/2023Barclays PLC18,225$91K0.0%+4,773.0%0.014%Search for SEC Filing on Google Icon
2/13/2023Renaissance Technologies LLC51,900$0.26M0.0%-19.2%0.041%Search for SEC Filing on Google Icon
2/13/2023Geode Capital Management LLC790,248$3.97M0.0%+31.4%0.626%Search for SEC Filing on Google Icon
2/9/2023Monashee Investment Management LLC2,230,441$11.22M4.8%+81.3%1.768%Search for SEC Filing on Google Icon
2/9/2023Citigroup Inc.126,315$0.64M0.0%+2,686.6%0.100%Search for SEC Filing on Google Icon
2/8/2023UBS Group AG11,819$59K0.0%+63.5%0.009%Search for SEC Filing on Google Icon
1/13/2023Flagship Harbor Advisors LLC11,500$58K0.0%-17.9%0.009%Search for SEC Filing on Google Icon
12/8/2022Bank of New York Mellon Corp24,251$55K0.0%N/A0.019%Search for SEC Filing on Google Icon
11/16/2022Jane Street Group LLC14,265$33K0.0%N/A0.011%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.2,380,623$5.43M0.0%+58.5%1.887%Search for SEC Filing on Google Icon
11/15/2022Marshall Wace LLP51,816$0.12M0.0%+118.4%0.041%Search for SEC Filing on Google Icon
11/15/2022Eventide Asset Management LLC1,100,399$2.51M0.0%N/A0.872%Search for SEC Filing on Google Icon
11/15/2022Bank of New York Mellon Corp24,251$55K0.0%N/A0.019%Search for SEC Filing on Google Icon
11/15/2022BlackRock Inc.872,497$1.99M0.0%+433.9%0.691%Search for SEC Filing on Google Icon
10/28/2022Silverarc Capital Management LLC262,090$0.60M0.2%N/A0.259%Search for SEC Filing on Google Icon
8/17/2022Salem Investment Counselors Inc.30,000$80K0.0%-70.0%0.030%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC27,861$74K0.0%-27.7%0.028%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC66,165$0.18M0.0%+397.5%0.065%Search for SEC Filing on Google Icon
8/8/2022CM Management LLC30,000$80K0.1%-90.0%0.030%Search for SEC Filing on Google Icon
7/13/2022Flagship Harbor Advisors LLC14,000$37K0.0%N/A0.014%Search for SEC Filing on Google Icon
7/8/2022New Capital Management LP24,243$69K0.0%N/A0.024%Search for SEC Filing on Google Icon
5/17/2022RA Capital Management L.P.532,958$0.73M0.0%-71.2%0.526%Search for SEC Filing on Google Icon
5/17/2022Farallon Capital Management LLC582,750$0.80M0.0%-41.7%0.575%Search for SEC Filing on Google Icon
5/12/2022Monashee Investment Management LLC1,270,211$1.74M0.5%-36.5%1.254%Search for SEC Filing on Google Icon
5/9/2022CM Management LLC300,000$0.41M0.3%N/A0.296%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd52,842$72K0.0%+81.9%0.052%Search for SEC Filing on Google Icon
2/15/2022Mirabella Financial Services LLP18,880$60K0.0%N/A0.019%Search for SEC Filing on Google Icon
2/15/2022Consonance Capital Management LP3,500,000$11.17M7.3%N/A3.570%Search for SEC Filing on Google Icon
2/15/2022Adage Capital Partners GP L.L.C.1,400,000$4.44M0.0%N/A1.428%Search for SEC Filing on Google Icon
2/14/2022LMR Partners LLP100,000$0.32M0.0%N/A0.102%Search for SEC Filing on Google Icon
2/14/2022DAFNA Capital Management LLC196,091$0.62M0.2%N/A0.200%Search for SEC Filing on Google Icon
2/11/2022Foresite Capital Opportunity Management V LLC1,100,000$3.49M2.3%N/A1.122%Search for SEC Filing on Google Icon
2/10/2022Qube Research & Technologies Ltd29,053$92K0.0%N/A0.030%Search for SEC Filing on Google Icon
2/10/2022Difesa Capital Management LP10,337$33K0.0%N/A0.011%Search for SEC Filing on Google Icon
2/7/2022Monashee Investment Management LLC2,000,000$6.34M1.6%N/A2.040%Search for SEC Filing on Google Icon
2/1/2022Qube Research & Technologies Ltd29,053$92K0.0%N/A0.030%Search for SEC Filing on Google Icon
1/28/2022New Capital Management LP24,243$77K0.0%N/A0.025%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Compass Therapeutics logo
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More on Compass Therapeutics

Today's Range

Now: $3.24
Low: $3.11
High: $3.29

50 Day Range

MA: $3.96
Low: $3.21
High: $5.48

52 Week Range

Now: $3.24
Low: $1.25
High: $5.65

Volume

331,261 shs

Average Volume

389,727 shs

Market Capitalization

$409.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Who are the company insiders with the largest holdings of Compass Therapeutics?

Compass Therapeutics' top insider investors include:
  1. Orbimed Advisors Llc (Director)
  2. Carl L Gordon (Director)
  3. Thomas J Schuetz (CEO)
  4. Vered Bisker-Leib (COO)
Learn More about top insider investors at Compass Therapeutics.

Who are the major institutional investors of Compass Therapeutics?

Compass Therapeutics' top institutional shareholders include:
  1. Vivo Capital LLC — 2.82%
  2. Monashee Investment Management LLC — 1.77%
  3. Braidwell LP — 1.44%
  4. Geode Capital Management LLC — 0.63%
  5. Alyeska Investment Group L.P. — 0.43%
  6. Susquehanna International Group LLP — 0.36%
Learn More about top institutional investors of Compass Therapeutics stock.

Which major investors are selling Compass Therapeutics stock?

In the last quarter, CMPX stock was sold by these institutional investors:
  1. Marshall Wace LLP
  2. Renaissance Technologies LLC
  3. Flagship Harbor Advisors LLC

Which major investors are buying Compass Therapeutics stock?

In the last quarter, CMPX stock was bought by institutional investors including:
  1. Braidwell LP
  2. Vivo Capital LLC
  3. Monashee Investment Management LLC
  4. Alyeska Investment Group L.P.
  5. Susquehanna International Group LLP
  6. Geode Capital Management LLC
  7. Citigroup Inc.
  8. Morgan Stanley
In the previous year, these company insiders have bought Compass Therapeutics stock:
  1. Orbimed Advisors Llc (Director)
  2. Carl L Gordon (Director)
  3. Thomas J Schuetz (CEO)
Learn More investors buying Compass Therapeutics stock.
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel